multiple dose studies [Design Issues]

posted by dshah  – India, 2024-03-12 18:37 (480 d 08:29 ago) – Posting: # 23905
Views: 3,166

Hello Loky do!

❝ I'm a little confused :confused: why to analyze solifenacin as it is immediate release and the concern towards tamsulosin as it is the delayed release one, even if I took into consideration the washout of both, are the results of solifenacin, in this case, affect those of tamsulosin?


Kindly refer section 3 of EMA guideline on FDC.
[image]

Considering as a sponsor, the analysis of solifenacin adds a cost. But as a regulator- if you are taking the sample- why it is not analyzed? Any SE relation with PK would not be feasible, then.

Regards,
Divyen

Complete thread:

UA Flag
Activity
 Admin contact
23,427 posts in 4,929 threads, 1,677 registered users;
20 visitors (0 registered, 20 guests [including 10 identified bots]).
Forum time: 04:06 CEST (Europe/Vienna)

Many people tend to look at programming styles and languages like religions:
if you belong to one, you cannot belong to others.
But this analogy is another fallacy.    Niklaus Wirth

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5